HOME >> BIOLOGY >> NEWS
Acamprosate: potential medication for treating alcoholism

laces and things associated with alcohol) and reduce alcohol consumption, leading to less relapse drinking and more abstinent days. Although it is well tolerated and does not produce many adverse effects, naltrexone does not work for everyone, leading some scientists to think there are genetic differences behind the treatment response.

For this study, adult participants (7 males, 3 females) were recruited through local advertising. All of the participants were classified as heavy drinkers, having reported alcohol consumption a minimum of eight days per month; with five or more drinks per occasion at least three times a month for the men, and four or more drinks per occasion at least three times a month for the women. During the six-week study, subjects received three different doses of oral acamprosate (0, 2 and 4 g.) for 11 days on each dose. Physiological, subjective and psychomotor measures were collected daily during each dosing cycle. During each of the acamprosate dose conditions, subjects also received three different doses of alcohol (0, 0.5 and 1.0 g/kg) during three separate laboratory sessions. Researchers collected the subjective, physiological and psychomotor effects of the alcohol as well as breath-alcohol levels at baseline and at 30-minute intervals for three hours following administration.

Results indicate that acamprosate does not appear to alter alcohol's pharmacokinetics (the way it moves through the body), acute physiological or psychomotor alcohol effects, or most subjective alcohol effects.

"While the results of this study are rather clear and straightforward, namely, that acamprosate has minimal effects on the alcohol experience, the findings should be interpreted cautiously because only a few subjects were studied and those subjects were not alcoholics," said Anton. "Since people vary in medication response, generalizing from a study of only a few people is difficult. Also, we know tha
'"/>


14-Jul-2004


Page: 1 2 3 4

Related biology news :

1. Award winning researchers reveal potential new role for Glivec
2. Evidence builds for potential new cancer drug target
3. Scientists discover potential new way to control drug-resistant bacteria
4. Tiny molecules have big potential as cancer drugs, Stanford researcher believes
5. OneWorld Health compiles comprehensive state of infectious diarrhea treatments, potential solutions
6. Managing occupational exposures to potential bioterrorist agents
7. Location of potential familial lung cancer gene discovered
8. Common chemicals morphing into potential toxins in Arctic
9. Yale researchers discover new potential asthma therapeutic targets related to parasites and insects
10. Researchers identify two potential protein targets for new drug therapies for pancreatic cancer
11. New screening method turns up potential compound for treating anthrax

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Acamprosate potential medication for treating alcoholism

(Date:8/22/2014)... the birds and the bees. But that old ... fertilized. The fertilization process for flowering plants is ... male and female reproductive cells. New research from ... Munich, and including Carnegie,s Wolf Frommer, David Ehrhardt, ... signaling process that guides flowering plant fertilization. It ...
(Date:8/21/2014)... -- Nxt-ID, Inc. (OTCQB: NXTD), a biometric authentication company ... that its shares of common stock and the warrants ... proposed underwritten public offering of common stock and warrants ... Market, subject to closing of its proposed underwritten public ... trade under the symbol "NXTD" and "NXTDW," respectively. ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- LiveScan Service ... agreed to a partnership with Gabriel Health Institute, ... fastest growing Certified Nursing Assistant preparatory schools. ...  an exclusive member of Binary,s LiveScan service provider,s ... will improve its service capabilities by widening ...
Breaking Biology News(10 mins):Calcium and reproduction go together 2Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
(Date:8/21/2014)...  BioSpecifics Technologies Corp. (NASDAQ: BSTC ... collagenase-based products marketed as XIAFLEX ® (collagenase ... XIAPEX ® in the EU, today announced ... Phase 2a study of CCH for the potential ... results showed that all three doses of CCH ...
(Date:8/21/2014)... DUBLIN, Ireland , August 21, 2014 ... and Markets ( http://www.researchandmarkets.com/research/3zh3q8/global_hormone ) has announced the ... Market 2014-2018"  report to their offering.  ... also known as hormone therapy, is a ... longer being produced by the body. This ...
(Date:8/21/2014)... NEW YORK , Aug. 21, 2014 Mathematic ... at Harvard University , and funded by the ... aggressive cells within tumors can be visually identified for elimination. ... tumor,s growth. The study, which shows a topological map of ... needed time in cancer research, for while tumor cells can ...
(Date:8/21/2014)... Ontotext S4 , The Self ... . Now the same enterprise hardened text mining, ... unstructured data is available to start-ups and mid-size businesses ... Organizations that do not have resources to evaluate and ... S4 since there is no need for on premise ...
Breaking Biology Technology:BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 2BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 3BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 4BioSpecifics Technologies Corp. Announces Positive Data from Phase 2a Study of CCH for Treatment of Cellulite 5Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk 2Science Power Jeffrey Epstein and Harvard University Fund Project to Visually Stop Tumor Growth 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 2Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 3Ontotext Releases Text Mining & Semantic Technology Running in the Cloud – Welcome to “S4? 4
Cached News: